Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study

BACKGROUND: Mesenchymal Consensus Molecular Subtype 4 (CMS4) colon cancer is associated with poor prognosis and therapy resistance. In this proof-of-concept study, we assessed whether a rationally chosen drug could mitigate the distinguishing molecular features of primary CMS4 colon cancer. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, Niek A., Constantinides, Alexander, Ubink, Inge, van Kuik, Joyce, Bloemendal, Haiko J., van Dodewaard, Joyce M., Brink, Menno A., Schwartz, Thijs P., Lolkema, Martijn P.J.K., Lacle, Miangela M., Moons, Leon M., Geesing, Joost, van Grevenstein, Wilhelmina M.U., Roodhart, Jeanine M. L., Koopman, Miriam, Elias, Sjoerd G., Borel Rinkes, Inne H.M., Kranenburg, Onno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486194/
https://www.ncbi.nlm.nih.gov/pubmed/36147916
http://dx.doi.org/10.3389/fonc.2022.969855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486194/
https://www.ncbi.nlm.nih.gov/pubmed/36147916
http://dx.doi.org/10.3389/fonc.2022.969855

Ejemplares similares